|
|
|
|
| LEADER |
01437nam a2200301 u 4500 |
| 001 |
EB001897161 |
| 003 |
EBX01000000000000001060166 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200523 r ||| eng |
| 100 |
1 |
|
|a Young, Calvin
|
| 245 |
0 |
0 |
|a Rapid genome-wide testing
|h Elektronische Ressource
|b a review of clinical utility, cost-effectiveness, and guidelines
|c Calvin Young, Charlene Argáez
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c September 20, 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (19 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Critical Care
|
| 653 |
|
|
|a Clinical Trials as Topic
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Whole Genome Sequencing
|
| 700 |
1 |
|
|a Argáez, Charlene
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK549546
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of the current report is to evaluate the clinical utility, cost-effectiveness, and evidence-based guidelines regarding the provision of rapid turnaround for genome-wide testing for patients in intensive care
|